can you take tirzepatide forever Do Need Mounjaro Forever? Weight Loss Duration Do I need to be

A 2025 JAMA Network Open cohort study found that most patients with overweight or obesity stopped dual-labeled GLP-1 receptor agonist therapy within 1 year

6 For adults with heart disease and obesity or overweight, along with a reduced-calorie diet and increased physical activity

The medications dual action on GLP-1 and GIP receptors makes it particularly effective for body weight control and glucose regulation during these challenging times

Designed for athletes, used by all

Clinical Appropriateness Framework Combination tesofensine-semaglutide therapy may theoretically apply to individuals with severe obesity (BMI 40 or 35 with comorbidities), inadequate single-agent response, or specific metabolic phenotypes involving both central appetite dysregulation and impaired glucose homeostasis

NICE guidance (CG189, PH53, and QS127) supports a structured, multi-component approach to weight management for those with obesity or complex needs